Results 171 to 180 of about 7,229 (203)

Usefulness of therapeutic drug monitoring of rilpivirine and its relationship with virologic response and resistance in a cohort of naive and pretreated HIV-infected patients

British Journal of Clinical Pharmacology, 2020
catherine DHIVER, Yazdan Yazdanpanah, Caroline Solas   +2 more
exaly  

Dolutegravir/rilpivirine

Reactions Weekly, 2018
openaire   +2 more sources

Suppression of Zika Virus Infection in the Brain by the Antiretroviral Drug Rilpivirine

Molecular Therapy, 2019
Andrew D Miller, Michael L Klein, Vincenzo Carnevale   +2 more
exaly  

Dolutegravir/rilpivirine

Reactions Weekly, 2017
openaire   +2 more sources

Dolutegravir–rilpivirine for virological suppression

The Lancet HIV, 2019
Anton L, Pozniak, Jose R, Arribas
openaire   +2 more sources

Rilpivirine Versus Efavirenz in HIV-1–Infected Subjects Receiving Emtricitabine/Tenofovir DF: Pooled 96-Week Data from ECHO and THRIVE Studies

HIV Clinical Trials, 2013
M R Nelson
exaly  

Rilpivirin

2013
openaire   +1 more source

Rilpivirine hydrochloride

2014
REDDY BANDI PARTHASARADHI, REDDY KURA RATHNAKAR, REDDY DASARI MURALIDHARA, REDDY ADULLA VENKAT NARSIMHA, KRISHNA BANDI VAMSI   +4 more
openaire   +2 more sources

Dolutegravir/rilpivirine

Reactions Weekly, 2019
openaire   +1 more source

Effect of food on rilpivirine/emtricitabine/tenofovir disoproxil fumarate, an antiretroviral single-tablet regimen for the treatment of HIV infection

Journal of Clinical Pharmacology, 2014
Andrew Cheng, Brian P Kearney, Srinivasan Ramanathan   +2 more
exaly